Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer

被引:20
作者
Hoshimoto, S. [1 ]
Hishinuma, S. [1 ]
Shirakawa, H. [1 ]
Tomikawa, M. [1 ]
Ozawa, I. [1 ]
Wakamatsu, S. [2 ]
Hoshi, S. [2 ]
Hoshi, N. [2 ]
Hirabayashi, K. [2 ]
Ogata, Y. [1 ]
机构
[1] Tochigi Canc Ctr, Dept Hepatobiliarypancreat Surg, 4-9-13 Yohnan, Utsunomiya, Tochigi 3200834, Japan
[2] Tochigi Canc Ctr, Dept Pathol, 4-9-13 Yohnan, Utsunomiya, Tochigi 3200834, Japan
来源
EJSO | 2017年 / 43卷 / 06期
关键词
Pancreatic neoplasms; Portal vein; Prognosis; Surgery; Survival; ADJUVANT CHEMOTHERAPY; CONSENSUS STATEMENT; ARTERIAL RESECTION; PANCREATICODUODENECTOMY; ADENOCARCINOMA; SURGERY; MANAGEMENT; FOLFIRINOX; OUTCOMES; NEED;
D O I
10.1016/j.ejso.2017.03.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The principal objective of this study is to clarify the prognostic significance of borderline resectable pancreatic cancer (BRPC). The second objective is to evaluate the prognostic impact of the depth of pathological venous invasion. Methods: The study included 122 pancreatic cancer patients who underwent curative surgery. All computed tomography scans of the patients were retrospectively interpreted and classified according to the NCCN guidelines, version 1.2016, as resectable (-) or borderline resectable (+) in each arterial (BR-A) and venous (BR-PV) involvement. Results: The overall survival (OS) rate was significantly higher in BR-A(-) patients (n = 94) than in BR-A(+) patients (n = 28) (P = 0.001), whereas there was no difference between BR-PV(-) (n = 101) and BR-PV(+) patients (n = 21) (P = 0.257). In a multivariate analysis, the independent predictors of OS included BR-A(+) (P = 0.002), lymph node metastasis (P = 0.008), pathological venous invasion (P = 0.003), and adjuvant chemotherapy (P = 0.001). Of 39 patients who underwent venous resection, no significant difference was observed between BR-PV(-) (n = 20) and BR -PV(+) patients (n = 19) in resection rate, lymph node metastasis, the presence of extrapancreatic nerve invasion, recurrence rate, frequency of initial recurrence at a liver or local site, and OS. Pathological venous invasion was significantly deeper in BR-PV(+) patients. However, the depth of invasion was not associated with OS. Conclusion: The definition of venous involvement in the current guidelines predicted the depth of pathological venous invasion but not OS in BRPC patients. Further prospective, randomized studies are needed to establish treatment strategies for BRPC patients with isolated venous involvement. (C) 2017 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:1068 / 1075
页数:8
相关论文
共 30 条
[1]   Is the Need for an Arterial Resection a Contraindication to Pancreatic Resection for Locally Advanced Pancreatic Adenocarcinoma? A Case-Matched Controlled Study [J].
Bachellier, Philippe ;
Rosso, Edoardo ;
Lucescu, Ionut ;
Oussoultzoglou, Elie ;
Tracey, Jacky ;
Pessaux, Patrick ;
Ferreira, Nelio ;
Jaeck, Daniel .
JOURNAL OF SURGICAL ONCOLOGY, 2011, 103 (01) :75-84
[2]   Justifying vein resection with pancreatoduodenectomy [J].
Barreto, Savio G. ;
Windsor, John A. .
LANCET ONCOLOGY, 2016, 17 (03) :E118-E124
[3]   Arterial en bloc resection for pancreatic carcinoma [J].
Bockhorn, M. ;
Burdelski, C. ;
Bogoevski, D. ;
Sgourakis, G. ;
Yekebas, E. F. ;
Izbicki, J. R. .
BRITISH JOURNAL OF SURGERY, 2011, 98 (01) :86-92
[4]   Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS) [J].
Bockhorn, Maximilian ;
Uzunoglu, Faik G. ;
Adham, Mustapha ;
Imrie, Clem ;
Milicevic, Miroslav ;
Sandberg, Aken A. ;
Asbun, Horacio J. ;
Bassi, Claudio ;
Buechler, Markus ;
Charnley, Richard M. ;
Conlon, Kevin ;
Cruz, Laureano Fernandez ;
Dervenis, Christos ;
Fingerhutt, Abe ;
Friess, Helmut ;
Gouma, Dirk J. ;
Hartwig, Werner ;
Lillemoe, Keith D. ;
Montorsi, Marco ;
Neoptolemos, John P. ;
Shrikhande, Shailesh V. ;
Takaori, Kyoichi ;
Traverso, William ;
Vashist, Yogesh K. ;
Vollmer, Charles ;
Yeo, Charles J. ;
Izbicki, Jakob R. .
SURGERY, 2014, 155 (06) :977-988
[5]   Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement [J].
Callery, Mark P. ;
Chang, Kenneth J. ;
Fishman, Elliot K. ;
Talamonti, Mark S. ;
Traverso, L. William ;
Linehan, David C. .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) :1727-1733
[6]   Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm? [J].
Christians, Kathleen K. ;
Tsai, Susan ;
Mahmoud, Anna ;
Ritch, Paul ;
Thomas, James P. ;
Wiebe, Lauren ;
Kelly, Tracy ;
Erickson, Beth ;
Wang, Huamin ;
Evans, Douglas B. ;
George, Ben .
ONCOLOGIST, 2014, 19 (03) :266-274
[7]   Surgical margins for duodenopancreatectomy [J].
Coppola, R. ;
Cartillone, M. ;
Borzomati, D. ;
Nappo, G. ;
Valeri, S. ;
Petitti, T. ;
Perrone, G. .
UPDATES IN SURGERY, 2016, 68 (03) :279-285
[8]  
ESPAC-5F, ESAC5F
[9]   Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer [J].
Ferrone, Cristina R. ;
Marchegiani, Giovanni ;
Hong, Theodore S. ;
Ryan, David P. ;
Deshpande, Vikram ;
McDonnell, Erin I. ;
Sabbatino, Francesco ;
Santos, Daniela Dias ;
Allen, Jill N. ;
Blaszkowsky, Lawrence S. ;
Clark, Jeffrey W. ;
Faris, Jason E. ;
Goyal, Lipika ;
Kwak, Eunice L. ;
Murphy, Janet E. ;
Ting, David T. ;
Wo, Jennifer Y. ;
Zhu, Andrew X. ;
Warshaw, Andrew L. ;
Lillemoe, Keith D. ;
Fernandez-del Castillo, Carlos .
ANNALS OF SURGERY, 2015, 261 (01) :12-17
[10]   Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection [J].
Flis, Vojko ;
Potrc, Stojan ;
Kobilica, Nina ;
Ivanecz, Arpad .
RADIOLOGY AND ONCOLOGY, 2016, 50 (03) :321-328